The short answer
IGF-1 LR3 is an engineered analogue of insulin-like growth factor 1: an 83-residue protein carrying a 13-residue N-terminal extension and an arginine substituted at position 3. Both modifications reduce binding to IGF binding proteins. It is a recombinant protein, not a synthesised peptide.
Key facts
- Length
- 83 residues
- Native IGF-1
- 70 residues, ~7.6 kDa
- Modifications
- 13-residue N-extension; Arg at position 3
- Purpose of both
- Reduce IGF binding protein affinity
- Disulfide bonds
- Three
- Produced by
- Recombinant expression
- UniProt (native)
- P05019
- WADA status
- Prohibited at all times, class S2
What the name encodes
Long R3 IGF-1. Long refers to the thirteen extra residues added at the N-terminus. R3 refers to arginine replacing the native glutamate at position 3. Both changes serve one purpose: reducing the analogue's affinity for the IGF binding proteins that normally sequester circulating IGF-1.
Why that design exists
In circulation, the overwhelming majority of IGF-1 is not free. It is bound to IGF binding proteins, largely in a ternary complex with IGFBP-3 and the acid-labile subunit, as Baxter reviewed in Hormone Research in 1994. Bound IGF-1 cannot engage its receptor. An analogue that escapes that sequestration has a much larger free fraction at the same total concentration.
Research material referenced
IGF-1 LR3 1mg, third-party HPLC tested
The design inversion worth noticing
Almost every other engineered compound in this catalogue does the opposite. Retatrutide and semaglutide add fatty acids to bind albumin. CJC-1295 with DAC binds albumin covalently. All of them add binding to extend duration. IGF-1 LR3 removes binding to increase availability. Same underlying bound-free equilibrium, engineered in opposite directions for different reasons.
Why it is a protein and not a peptide
At 83 residues with three disulfide bonds and a folded tertiary structure, this is a small protein. It is produced by recombinant expression in host cells rather than by stepwise chemical synthesis, and that difference runs through everything: what impurities exist, what a purity figure means, and what quality control has to test for.
Where it came from
Its established use is as a cell culture supplement, where resistance to binding proteins secreted by cultured cells makes it more consistently available than native IGF-1. That is a laboratory reagent application, and it is the context the compound was developed for.
Regulatory and prohibited status
IGF-1 LR3 holds no marketing authorisation anywhere. A licensed recombinant human IGF-1 does exist (mecasermin, marketed as Increlex), but that is native rhIGF-1 and a different molecule. IGF-1 and its analogues are on the WADA Prohibited List under class S2, prohibited at all times in and out of competition.
Frequently asked questions
What does LR3 stand for?
Long R3: a 13-residue N-terminal extension, and arginine substituted for glutamate at position 3.
Is it a peptide?
It is a small protein: 83 residues with three disulfide bonds and a folded structure, made recombinantly rather than synthesised.
Is it prohibited in sport?
Yes. IGF-1 and its analogues are on the WADA Prohibited List under class S2, prohibited at all times.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedBaxter RC, Insulin-like growth factor binding proteins in the human circulation: a review. Horm Res 1994 (PMID 7532612)pubmed.ncbi.nlm.nih.gov
- PubMedMilner SJ et al., Mutations in the B-domain of insulin-like growth factor-I influence oxidative folding. Biochem J 1995 (PMID 8948444)pubmed.ncbi.nlm.nih.gov
- RefUniProt · IGF-1 (P05019)uniprot.org
- RefWADA Prohibited Listwada-ama.org
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More IGF-1 LR3 articles
- IGF Binding Proteins and the Free FractionMost circulating IGF-1 is sequestered in a ternary complex with IGFBP-3 and the acid-labile subunit. That system is what LR3 was designed to evade.
- IGF-1 LR3 Structure: Three Disulfides and Why They Matter83 residues folded by three disulfide bonds. Milner 1995 showed B-domain mutations affect oxidative folding - and position 3 is in the B-domain.
- Recombinant Versus Synthetic: Two Different Quality ProblemsA recombinant protein has host cell proteins, DNA and endotoxin as impurities. A synthetic peptide has deletion sequences. The certificates should differ.
- IGF-1 LR3 Against the Native Hormone70 residues against 83, and a completely different relationship with binding proteins. Why one is an approved medicine and the other is not.
- Why LR3 Exists: The Cell Culture ApplicationCultured cells secrete their own binding proteins, which sequester added IGF-1 unpredictably. An analogue that resists them gives consistent availability.